Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Yale University |
---|---|
Information provided by: | Yale University |
ClinicalTrials.gov Identifier: | NCT00676026 |
The goal of this series of challenge studies is to examine the impact of menstrual cycle phase on cortical GABA response to administration of agents with either direct (benzodiazepines) or indirect (progesterone, fluoxetine) GABA modulating properties. While the impact of these agents on cortical GABA levels in women with premenstrual dysphoric disorder (PMDD) is of interest, this study is designed primarily for those women without a psychiatric illness.
Condition | Intervention |
---|---|
Healthy |
Drug: Fluoxetine Drug: Zolpidem Drug: Progesterone |
Study Type: | Interventional |
Study Design: | Non-Randomized, Single Blind (Subject), Active Control, Single Group Assignment |
Official Title: | The Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women |
Enrollment: | 5 |
Study Start Date: | May 2005 |
Estimated Study Completion Date: | May 2010 |
Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Zolpidem 1: No Intervention
Zolpidem will be administered twice to each participant; once in the follicular and luteal phases of the menstrual cycle.
|
Drug: Zolpidem
Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
|
Progesterone 2: No Intervention
Progesterone will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
|
Drug: Progesterone
Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.
|
Fluoxetine 3: No Intervention
Fluoxetine will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
|
Drug: Fluoxetine
Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
|
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Connecticut | |
Yale University School of Medicine; Yale Program for Women's Reproductive Behavioral Health | |
New Haven, Connecticut, United States, 06511 |
Principal Investigator: | Cynthia N Epperson, MD | Yale School of Medicine |
Responsible Party: | Yale University School of Medicine Department of Psychiatry ( C. Neill Epperson, M.D. ) |
Study ID Numbers: | 0505027759 |
Study First Received: | April 7, 2008 |
Last Updated: | May 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00676026 |
Health Authority: | United States: Institutional Review Board |
menses women healthy controls Healthy females with regular menstrual cycles |
Fluoxetine Zolpidem Progesterone Healthy Serotonin |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Psychotropic Drugs Central Nervous System Depressants Hormones Serotonin Uptake Inhibitors Pharmacologic Actions |
Serotonin Agents GABA Agonists Therapeutic Uses Progestins Hypnotics and Sedatives GABA Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |